Clinical Updates on Atopic Dermatitis Treatment

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dermatology".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 1712

Special Issue Editor


E-Mail Website
Guest Editor
Faculty of Pharmaceutical Sciences, Josai University, Sakado, Japan
Interests: barrier function; sphingolipids metabolism; cornification

Special Issue Information

Dear Colleagues,

Atopic dermatitis (AD) is one of the common chronic inflammatory skin diseases worldwide, with pruritus as a primary lesion. Although AD is most often diagnosed in childhood, many adults experience the disease even after the age of 18. AD is associated with multiple triggers and mechanisms; thus, the treatment of AD is complex, and many drugs and therapeutic targets are given. The main current strategies to treating AD are daily skincare used to moisturize and improve the cutaneous barrier dysfunction and medical treatments taken to control the itching and inflammation. However, it is hard to keep AD patients in remission. Recently systemic treatments, such as Janus kinase inhibitors and interleukin receptor inhibitors, have proven efficacious in AD. The aim of this Special Issue is to provide a comprehensive overview of advances in the diagnosis and treatment of AD, with particular interest on the use of innovative techniques and technologies in interventional therapies. Therefore, researchers in the field of AD are encouraged to submit their findings as original articles or reviews to this Special Issue.

Prof. Dr. Yutaka Takagi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • skincare
  • proactive therapy
  • calcineurin inhibitors
  • systemic treatment
  • biologics
  • pediatrics
  • pruritus

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

15 pages, 769 KiB  
Review
Efficacy of Topical Application of a Skin Moisturizer Containing Pseudo-Ceramide and a Eucalyptus Leaf Extract on Atopic Dermatitis: A Review
by Yutaka Takagi
J. Clin. Med. 2024, 13(6), 1749; https://doi.org/10.3390/jcm13061749 - 18 Mar 2024
Cited by 1 | Viewed by 1492
Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with pruritus, an impaired cutaneous barrier function and a disrupted water holding capacity. Levels of ceramides, which are major components of intercellular lipids and are crucial for their functions, are decreased in the [...] Read more.
Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with pruritus, an impaired cutaneous barrier function and a disrupted water holding capacity. Levels of ceramides, which are major components of intercellular lipids and are crucial for their functions, are decreased in the stratum corneum of patients with AD. Treatments to increase ceramide levels are effective for AD care. Synthetic pseudo-ceramide (cetyl PG hydroxyethyl palmitamide (SLE66)), which has a structure developed via molecular designs, and a eucalyptus leaf extract (ELE) enhance ceramide synthesis in the epidermis. The topical application of a skin moisturizer containing SLE66 and ELE improves the barrier functions and water holding capacity of AD skin accompanied by an improvement in skin symptoms. This is a multifaceted review that summarizes the efficacy of the topical application of a skin moisturizer containing SLE66 and ELE on atopic dermatitis. Full article
(This article belongs to the Special Issue Clinical Updates on Atopic Dermatitis Treatment)
Show Figures

Figure 1

Back to TopTop